Kowa Pharmaceuticals America, Inc.
Kowa Pharmaceuticals America, Inc., headquartered in Montgomery, Alabama, is committed to continuing the development and commercialization of safe, effective healthcare solutions primarily in the area of cardiometabolic diseases. Established in September 2008, Kowa Pharmaceuticals America focuses its efforts on the successful commercialization of its current and near-term portfolio of pharmaceutical products and business development activities.
Kowa Company, Ltd.
Kowa Company, Ltd., is a privately held, multinational company headquartered in Nagoya, Japan. Established in 1894, Kowa is actively engaged in various manufacturing and trading activities in the fields of pharmaceuticals, life science, information technology, textiles, machinery and various consumer products. Kowa's pharmaceutical division is focused on research and development for cardiovascular therapeutics (dyslipidemia, type 2 diabetes and atherosclerosis), ophthalmology and anti-inflammatory agents. The company’s flagship product, LIVALO® (pitavastatin), is approved in 45 countries around the world.
The Kowa Pharmaceuticals America, Inc. management team is comprised of individuals dedicated to innovation, consistency and quality, all in service of the physicians and patients who rely on our products.
The following individuals share a vision and pragmatism that ensure the stable and sustained growth of Kowa Pharmaceuticals America, Inc.